Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 million lives. Mult...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering ...

NTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore in the state.

Dixon Technologies and Chinese smartphone maker Vivo are entering into a joint venture that will manufacture smartphones for the smartphone...

Markets advanced nearly 1% last week, recording a two-week rally. Focus today includes Greaves Cotton's IPO plan for its subsidiary, Biocon...

Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions...